Work

Perioperative Dexmedetomidine and Ketamine Infusions for Multimodal Analgesia Following Bariatric Surgery: A Randomized Double-Blind Placebo-Controlled Trial

Year: 2026
Type: preprint
Abstract: Background Effective postoperative pain control after bariatric surgery is challenging due to high opioid requirements and associated adverse effects. Dexmedetomidine and ketamine are widely used as adjuncts in multimodal analgesia; however, their comparative efficacy remains unclear. This study aimed to compare perioperative dexmedetomidine and ketamine infusions on postoperative analgesia and recovery outcomes following bariatric surgery. Methods Ninety-six patients undergoing elective bariatric surgery were randomly assigned to dexmedetomidine, ketamine, or placebo groups (n = 32 each). Dexmedetomidine was administered as a 0.5 µg/kg loading dose followed by 0.3 µg/kg/h infusion, and ketamine as a 0.5 mg/kg loading dose followed by 0.25 mg/kg/h infusion; placebo received normal saline. Infusions were discontinued 10 minutes before the end of surgery. Anesthetic management was standardized across groups. The primary outcome was postoperative pain intensity measured using the Numeric Rating Scale (NRS) in the post-anesthesia care unit (PACU) and at 30, 60, and 120 minutes. Secondary outcomes included 24-hour opioid consumption, sedation level, postoperative nausea and vomiting (PONV), patient satisfaction, and adverse events. Results Baseline characteristics were comparable among groups (P > 0.05). Dexmedetomidine significantly reduced postoperative pain scores at all time points compared with ketamine and placebo (P < 0.001). Ketamine showed only transient analgesic effects at 30 and 60 minutes. Opioid consumption was significantly lower in the dexmedetomidine group compared with ketamine and placebo (P < 0.001), while no significant difference was observed between ketamine and placebo (P = 0.105). Patient satisfaction was significantly higher in the dexmedetomidine group (P < 0.001). Sedation was higher early postoperatively with dexmedetomidine but normalized within 2 hours. No significant differences were observed in PONV or adverse events among groups. Conclusion Dexmedetomidine provides superior and sustained postoperative analgesia and reduces opioid consumption compared with ketamine and placebo in bariatric surgery, with acceptable safety. Ketamine offers only short-term analgesic benefit without meaningful opioid-sparing effects. Trial Registration Iranian Registry of Clinical Trials (IRCT): IRCT20230518058225N8, registered on January 6, 2025.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7237207654
Cites: 16
Cited by:
Related to: 10